- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Amgen-Allergan Rituximab Candidate Meets Test for Biosimilarity
Results of an analytical similarity test provide additional evidence in support of a biologics license application filed with the FDA by Amgen and Allergan.
An analytical similarity assessment has demonstrated that the Amgen and Allergan rituximab biosimilar candidate (ABP 798) is structurally and functionally similar to its reference biologic counterparts marketed in the United States and Europe.
Amgen, of Thousand Oaks, California, and Allergan, based in Dublin, Ireland, submitted a biologics license application to the FDA for review of ABP 798 in December 2019. ABP is a CD20-directed antibody that promotes cancer cell death through cytolysis, or excess fluid absorption. The reference product is indicated for treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis.
The analytical assessment evaluated the antigen binding properties of ABP 798 and demonstrated that ABP 798 has similar amino acid sequence; structure; glycan profile, which relates to pharmacodynamic and pharmacokinetic attributes; and biological activity. There were minor differences in biochemical attributes that were not considered clinically meaningful.
The authors of the study concluded that ABP 798 is “highly analytically similar” to the reference rituximab product (Rituxan [United States], MabThera [European Union]) and said the findings support use of ABP 798 in all approved indications of the reference product.
ABP 798 was developed to offer the same strength and dosage approved for reference rituximab in the United States and Europe: 10 mg/mL in 100-mg and 50-mg single-use vials for intravenous administration. The study evaluated active and inactive ingredients to assess safety, efficacy, and product quality of the biosimilar candidate.
Amgen developed the biosimilar and is collaborating with Allergan to develop and commercialize 4 oncology antibody biosimilars, including ABP 798. Allergan became a property of AbbVie in May 2020.
There are 2 rituximab biosimilars on the market in the United States currently: Ruxience (Pfizer) and Truxima (Celltrion/Teva).
Reference
Seo N, Huang Z, Kuhns S. Analytical and functional similarity of biosimilar ABP 798 with rituximab reference product. Biologicals. Published online September 1, 2020. doi:10.1016/j.biologicals.2020.08.002
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.
